Menu Search
Equities

Mirum Pharmaceuticals Inc

08D:FRA

Mirum Pharmaceuticals Inc

Actions
  • Price (EUR)40.80
  • Today's Change-0.20 / -0.49%
  • Shares traded100.00
  • 1 Year change+40.69%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

  • Revenue in USD (TTM)307.03m
  • Net income in USD-99.81m
  • Incorporated2018
  • Employees311.00
  • Location
    Mirum Pharmaceuticals Inc989 EAST HILLSDALE BOULEVARD, SUITE 300FOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 667-4085
  • Fax+1 (302) 269-3855
  • Websitehttps://mirumpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.